BACKGROUND: Understanding the drug development pathway is critical for streamlining the development of effective cancer treatments. The objective of the current study was to delineate the drug development timeline and attrition rate of different drug classes for common cancer disease sites. METHODS: Drugs entering clinical trials for breast, colorectal, and non-small cell lung cancer were identified using a pharmaceutical business intelligence database. Data regarding drug characteristics, clinical trials, and approval dates were obtained from the database, clinical trial registries, PubMed, and regulatory Web sites. RESULTS: A total of 411 drugs met the inclusion criteria for breast cancer, 246 drugs met the inclusion criteria for colorectal cancer, and 315 drugs met the inclusion criteria for non-small cell lung cancer. Attrition rates were 83.9% for breast cancer, 87.0% for colorectal cancer, and 92.0% for non-small cell lung cancer drugs. In the case of non-small cell lung cancer, there was a trend toward higher attrition rates for targeted monoclonal antibodies compared with other agents. No tumor site-specific differences were noted with regard to cytotoxic chemotherapy, immunomodulatory, or small molecule kinase inhibitor drugs. Drugs classified as "others" in breast cancer had lower attrition rates, primarily due to the higher success of hormonal medications. Mean drug development times were 8.9 years for breast cancer, 6.7 years for colorectal cancer, and 6.6 years for non-small cell lung cancer. CONCLUSIONS: Overall oncologic drug attrition rates remain high, and drugs are more likely to fail in later-stage clinical trials. The refinement of early-phase trial design may permit the selection of drugs that are more likely to succeed in the phase 3 setting. Cancer 2017;123:4672-9.
INTRODUCTION
Drug development expenditures are a critical concern in oncology. A recent study revealed that costs related to drug development represented 27% of the e51.0 billion spent on cancer-related health care in the European Union in 2009. 1 Increasing risk, costs, and inefficiency all are inversely linked to industry productivity, which has declined as a result. 2 In 2004, the US Food and Drug Administration (FDA) identified the drug market approval process as "long, costly and inefficient," leading to the creation of the Critical Path Initiative to drive innovation. 3 This initiative outlined opportunities for new scientific discoveries in fields such as genomics and imaging to be applied during drug development to improve accuracy and efficiency. Although improvements have been made since then, 4 drug development expenditures continue to rise, with the average development cost now nearing US$2.6 billion, and costs increasing 8.5% above inflation annually. 5 When compared with other therapeutic indications, oncology drugs more often are first-in-class, biotechnology, or orphan medications, 6, 7 indicating their integral role in the introduction of innovative compounds. Oncology drugs also are more likely to receive priority review by the FDA and to be part of programs to expedite drug development. 7, 8 However, despite their clinical and economic relevance, oncology medications have rates of discontinuation during development, also described as drug attrition rates, that are 2 to 4 times as high as those for drugs for nononcology indications, 9, 10 and are more likely to fail during a phase 3 randomized controlled trial rather than in early-phase studies. 7, 11 A study by Kola and Landis found oncology drugs to have a clinical success rate, from first-in-human to drug registration, of only 5% 10 ; In 2014, Hay et al analyzed approval rates for 5820 drugs for various indications, including 1803 oncologic medications, and found a likelihood of approval of 7% for oncology medications, which was the lowest likelihood of any indication they studied. 9 Another study by DiMasi and Grabowski found that although oncologic and nononcologic medications had similar marketing approval success rates, oncologic medications were more likely to fail after entering phase 3 trials. 7 They suggested that the bottleneck in oncologic drug development lies in the identification of disease-specific activity.
The objective of the current study was to characterize oncology drug attrition rates for various classes of medications entering clinical trials from 1979 to 2014 in 3 common oncologic sites: breast, colorectal, and nonsmall cell lung cancers. Drug development times for each tumor site also were evaluated.
MATERIALS AND METHODS
The Citeline Pharmaprojects (http://www.citeline.com) pharmaceutical business intelligence database (which lists drug information dating back to 1979) was used to identify and screen all drugs entering clinical trials for breast, colorectal, and non-small cell lung cancers in North America and/or Europe between January 1, 1979 and October 27, 2014. Inclusion criteria were that the drug entered clinical trials within the defined time period and at least one trial was conducted specifically for the tumor site. Exclusion criteria were having only preclinical data available and having no study specifically focusing on one clinical indication. Information regarding drug characteristics, clinical trials, and governmental approval dates was collected using multiple databases, including Pharmaprojects, PubMed, ClinicalTrials.gov, the European Union Clinical Trials Register, and US FDA Web sites.
Drugs then were classified into 1 of 5 categories by 2 researchers: 1) cytotoxic chemotherapy; 2) targeted monoclonal antibody; 3) small molecule kinase inhibitor; 4) cancer vaccine/immunomodulator; and 5) others.
Drug success and attrition rates were determined using the phase transition probability (PTP) metric (equation 1 in Fig. 1 ) developed by DiMasi and Grabowski. 7 This method (which is applicable to drugs developed for both oncologic and nononcologic indications 9 ) assumes that drugs currently still in development will advance phases at rates similar to the calculated PTP. Overall drug transition probability (DTP) from phase 2 to registration was calculated as the product of each individual PTP (equation 2 in Fig. 1 ).
7,9 Phase 2 to registration was chosen based on the inclusion criteria of the study, because drugs were selected based on having had at least one disease site-specific trial. Attrition rates were calculated by subtracting the PTP (or DTP) from 100%.
To analyze the development duration for each drug, we defined the start date for each phase of development as the month of first patient recruitment in the earliest available trial identified across all databases searched. We defined the end date of each phase based on the trial completion date if this was available or the trial publication date if a completion date was not available. Outliers were defined as drugs having development times that differed by at least 65 years from the tumor site average development time.
Statistical Analysis
Descriptive statistics were used to analyze baseline drug characteristics. Drug attrition rates and PTPs between tumor sites and drug classes were compared using chisquare and Fisher exact tests.
RESULTS
A total of 724 breast cancer drugs, 629 colorectal cancer drugs, and 591 non-small cell lung cancer drugs were identified from the Pharmaprojects database. Of these, 411 drugs for breast cancer, 246 drugs for colorectal cancer, and 315 drugs for non-small cell lung cancer met the study inclusion criteria. Characteristics of the drugs developed for each tumor site are listed in Table 1 . A larger percentage of breast cancer drugs fell into the "others" category compared with drugs for colorectal and non-small cell lung cancer (P 5 .02), which was driven largely by hormonal therapies for this particular tumor site. When comparing the 3 tumor sites, the percentage of drugs studied in each of the drug classes was similar. Major contributors to the "others" category observed for all tumor sites were modulators of angiogenesis and cellular metabolism with unique mechanisms of action.
Phase Transition Probabilities
Overall, 25 breast cancer drugs (6.1%), 12 colorectal cancer drugs (4.9%), and 10 non-small cell lung cancer drugs (3.2%) were approved by the US FDA (P 5.19). The DTP (from phase 2 trial to FDA approval) was 14.1% for breast cancer drugs, 13.0% for colorectal cancer drugs, and 8.0% for non-small cell lung cancer drugs. This translates into attrition rates of 85.9% for breast cancer drugs, 87.0% for colorectal cancer drugs, and 92% for non-small cell lung cancer drugs. Figure 2 demonstrates the PTPs for each tumor site across each phase of drug development. PTPs across all tumor sites were higher for (24) 55 (13) 86 (21) 45 (11) 125 ( 65 (26) 49 (20) 48 (20) 34 (14) 50 (20) 246 (100) Non-small cell lung cancer, no. (%)
80 (25) 51 (16) 74 (24) 31 (10) 79 (25) 315 (100) a The "others" category was comprised mainly of endocrine therapy, modulators of angiogenesis, and modulators of cellular metabolism. b Statistically significant at P 5 .002. phase 1 to phase 2 transitions compared with subsequent phases (P<.01). There were no differences noted between tumor sites in transition from phase 1 to phase 2 (P 5.12) and phase 2 to phase 3 (P 5 .34) trials. There was a trend toward a lower transition probability of drugs entering phase 3 trials to FDA approval for non-small cell lung cancer (19.2%) compared with breast (37.9%) or colorectal (40.0%) cancers, but this did not reach statistical significance (P 5.054). Analysis of the PTP and DTP for each tumor site by drug class is shown in Table 2 . The overall DTP for drugs classified as "others" in the current study was higher in breast cancer (13.6%) compared with colorectal cancer (4.4%) or non-small cell lung cancer (0.0%). On further analysis of this group (see Supporting Information Table 1 ), hormonal therapies in breast cancer had an overall DTP of 35.5% (45 drugs), whereas nonhormonal therapies for breast cancer categorized as "others" had an overall DTP of 0% (80 drugs). The DTP for monoclonal antibodies was lower in non-small cell lung cancer than in colorectal or breast cancer. In addition, the DTP for small molecule kinase inhibitors in non-small cell lung cancer drugs was approximately 10% higher than in breast or colorectal cancer drugs. Among immunomodulators and vaccines, only colorectal cancer drugs had a DTP >0%. DTPs were similar between all tumor sites for cytotoxic chemotherapy.
Immunomodulators and cancer vaccines were found to be less likely to transition from phase 1 to phase 2 for breast cancer than for colorectal cancer or non-small cell lung cancer (62.5% vs 87.9% vs 89.7%, respectively; P 5.007). Cytotoxic chemotherapy medications were less likely to transition from phase 1 to phase 2 development for colorectal cancer (85.9%) compared with breast cancer (95.0%) or non-small cell lung cancer (97.5%), respectively (P 5.01). In addition, small molecule kinase inhibitors were less likely to transition from phase 2 to phase 3 development for breast cancer than for colorectal or nonsmall cell lung cancer (P 5.008). Monoclonal antibodies were less likely to transition from phase 3 trials to FDA approval in non-small cell lung cancer compared with colorectal cancer (0.0% vs 100.0%, respectively; P 5.002), with a trend toward statistical significance compared with breast cancer as well (57.1%; P 5.07). Finally, drugs classified as "others" in the current study were more likely to transition from phase 3 development to FDA approval in breast cancer than in lung cancer (34.5% vs 0.0%, respectively; P 5.03). No other significant differences in PTP were noted across tumor sites for each of the drug classes. Drugs initially were divided by decade based on the date of the first phase 2 clinical trial. However, due to small sample sizes between 1979 and 2000, these drugs were combined into one group for analysis. The phase 2 to phase 3 PTP for all cancer types was 36.6% (104 drugs) from 1979 to 2000, 27.6% (425 drugs) from 2001 to 2010, and 42.5% (104 drugs) from 2011 to 2014 (P 5.06). Figure 3 demonstrates the phase 2 to phase 3 PTP for breast, colorectal, and non-small cell lung cancer drugs within each group.
Drug Development Times
Overall drug development times from the start of phase 1 to the end of phase 3 trials were 8.9 years for breast cancer, 6.7 years for colorectal cancer, and 6.6 years for nonsmall cell lung cancer (P 5.54). The mean duration of each phase of development for each tumor site is listed in Table 3 . When comparing the mean development time of drugs approved before introduction of the FDA's Critical Path Initiative in 2004 (8.7 years) with drugs approved after the introduction of this program (7.2 years), no statistically significant difference was found (P 5.45) (see Supporting Information Table 2 ). For breast cancer, no FDA-approved drugs were identified as outliers. For colorectal cancer, tipiracil/trifluridine had a total development time of 15.5 years and were classified as outliers. For lung cancer, paclitaxel was an outlier, with a development time of 13.9 years.
DISCUSSION
Using multiple sources of drug development information, the current study found that drug attrition rates in oncology remain high across all tumor sites. The results of the current study also demonstrate that many oncologic drugs fail in the more expensive later phases of development.
One possible explanation for the varying attrition rates for different tumor sites relates to the fact that during the time period studied there were fewer clinical trials of targeted therapies performed in non-small cell lung cancer compared with breast and colorectal cancers. With recent advances in immune therapy 12, 13 and targeted agents 14, 15 against non-small cell lung cancer, there is a possibility that success rates for this type of cancer may change if we repeat the current study at a future time.
Conversely, breast cancer had the highest rate of FDA drug approval, which is likely due to the success of endocrine therapies in this cancer disease site during the time period studied. In fact, every successful drug in the "others" category for breast cancer was an endocrine treatment. It is interesting to note that more drugs entered trials specifically for breast cancer (411 drugs) than for colorectal cancer (246 drugs) or non-small cell lung cancer (315 drugs). The availability of research funding contributes to this discrepancy, because multiple studies have shown significant research expenditure on breast cancer, even to a level that is disproportionately high to the burden of disease. [16] [17] [18] An example of this is the National Cancer Institute funding for breast cancer research in 2013 of US$559.2 million compared with US$238.2 million for colorectal cancer research and US$285.9 million for lung cancer research. 19 
Phase Transition Probabilities
Because of our inclusion criteria, the PTPs between phase 1 and phase 2 across all tumor sites in the current study are higher than those presented in other studies. The lowest PTPs occurred in the move from phase 2 to phase 3 trials for both breast (36.1%) and colorectal (31.4%) cancer drugs, whereas the lowest PTP for non-small cell lung cancer was between phase 3 and FDA approval (19.2%).
These trends are supported by prior studies that have suggested that later-phase trials focused on finding diseasespecific activity are the rate-limiting step in oncologic drug development. 7, 11 However, given that average development costs during phase 3 (US$255.4 million) are reported to be 10 times greater than costs during phase 1 (US$25.3 million) for a drug, 5 the refinement of earlier phases of development may result in significant savings. With improved understanding of the pathophysiology of cancer, better drugs and preclinical studies are possible, thereby allowing for the earlier identification of drugs that are likely to fail and the more accurate selection of drugs that are likely to succeed. There is evidence that this occurred in the 1990s, because in the year 2000 <10% of drug attrition was attributable to concerns with pharmacokinetics or bioavailability (compared with approximately 40% in 1991); this may reflect a better understanding of in vitro methods with which to screen for absorption and metabolism. 20 When comparing drug classes across tumor sites, the results of the current study suggested a trend toward higher attrition rates for targeted monoclonal antibodies in non-small cell lung cancer. This may be due to the fact that 60% (9 of 15 drugs) of the targeted monoclonal antibodies entering phase 3 testing for non-small cell lung cancer remained under active study at the data collection cutoff date for the current study. The lower attrition rates for drugs classified as "others" in breast cancer research is entirely attributable to the higher success rates of endocrine therapies for this cancer site. The current study data do not suggest any benefit to prioritizing the development of any particular drug class in any specific cancer disease site, other than endocrine therapies for breast cancer.
The current study found DTPs that were higher than those identified by Hay et al for breast and colorectal cancer, but found similar DTPs for non-small cell lung cancer (Table 4) . 9 The results of the current study demonstrated a higher PTP across all tumor sites for phase 1 to phase 2, compared with the phase 1 to phase 2 PTP of 76.8% noted by DiMasi and Grabowski. 7 The higher phase 1 to phase 2 PTP in the current study most likely is due to the exclusion of drugs that failed to demonstrate any tumor-specific benefit in early-phase clinical trials for breast, colorectal, or non-small cell lung cancer. However, our phase 2 to phase 3 PTPs also were higher than those found by Hay et al 9 across all tumor sites, although they were lower than the PTP of 59.4% reported by DiMasi and Grabowski for this development period. Moreover, the current study did not find an improvement in phase 3 to FDA approval PTPs when compared with the study by Hay et al, 9 despite limiting the data set in the current study to drugs with disease-specific trials. This finding supports the hypothesis that improvements in early-phase trial design to identify clinically meaningful activity before moving to phase 3 may help to prioritize drugs that are likely to succeed, and could substantially reduce attrition rates.
Drug Development Times
Overall drug development times were found to be similar across all 3 tumor types, and generally were consistent with the average development time of 7.8 years previously reported by DiMasi and Grabowski. 7 It is interesting to note that despite the introduction of the Critical Path Initiative in 2004, the mean development time for cancer medications did not change. Further study into factors affecting drug development time is required to fully understand the delays in the drug development process, and the impact of programs such as the Critical Path Initiative on drug development times.
Limitations and Future Directions
Although the current study made extensive use of multiple data sources to ensure adequate data quality, several limitations exist. First, not all drugs follow the "traditional" drug development process. For example, some drugs were granted FDA approval after phase 2 studies, such as capecitabine for breast cancer. 21 In these instances, the phase 3 trial recruited patients after drug approval already had occurred, thereby introducing potential error into drug development time calculations. Second, to the best of our knowledge, many phase 1 trials conducted by pharmaceutical companies are not reported in clinical trial registries or published in medical journals. Although the use of a business intelligence database helped to mitigate this limitation, the start and end dates for many phase 1 trials were not available, again impacting drug development time calculations.
The global generalizability of the current study data are limited because FDA approval data were used to represent final drug approval. However, the generalizability of the results of the current study is enhanced by our use of the European Union Clinical Trials Register and the inclusion of clinical trials indexed in PubMed, which represent the international community. Finally, as previously noted by DiMasi and Grabowski, 7 the PTP formula assumes that future drugs will have attrition rates similar to the drugs that came before them; this assumption may not hold true, especially for rapidly evolving areas such as monoclonal antibodies and immunotherapy in non-small cell lung cancer.
Future research can focus on observing changes in drug attrition rates over time as cancer drug development moves toward targeted therapies, 13, 14, 22 genomic medicine, 23 and immunotherapy. Although it was beyond the scope of the current study, the information collected herein may be used to identify predictors of drug development failure. Previous studies have consistently shown that among drugs failing in later stages of development, there is a lack of biomarker stratification in comparison with those drugs that succeed. 24, 25 Although targeted agents and biomarker selection may result in more efficient drug development, it limits the population in which the drug may be effective, and can make the design and recruitment for clinical trials costlier. 26 Further exploration of these competing costs and benefits would be of interest in future studies.
Conclusions
The results of the current study confirmed that attrition rates remain very high for oncologic drugs, and that many oncologic medications fail in more expensive phase 2 and phase 3 studies. We did not find any significant Original Article differences in attrition rates for various drug classes for breast, colorectal, or non-small cell lung cancer (except for hormonal therapies in breast cancer, which have lower attrition rates). Although a trend existed toward higher attrition rates for targeted antibodies in lung cancer, many trials remain ongoing, and further research will be required in this subgroup. Overall, as our knowledge of cancer biology and pathophysiology improves, innovations in early-phase trial design may reduce drug attrition rates and accelerate the drug development process.
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